Zydus commences Phase 3 trials of Lipaglyn in patients suffering from Lipodystrophy

Zydus Group, exploring newer therapeutic usage of its breakthrough drug Lipaglyn (Saroglitazar), has now initialed Phase III trials of the molecule for patients suffering from Lipodystrophy. The drug is already approved in India for treating diabetic dyslipidemia and hypertriglyceridemia. The goal of this trial is to evaluate the safety and efficacy of Lipaglyn 4 mg versus standard- of-care with placebo in the treatment of Lipodystrophy. Lipodystrophy is a problem with the way the body produces, uses, and store fat. Inherited Lipodystrophies are caused by mutations in a gene. Acquired Lipodystrophies are caused by medications, autoimmune mechanism or unknown mechanisms. Patients with Lipodystrophy suffer from metabolic disorders including lipid disorder and insulin resistance that leads to diabetes. These disorders can also increase the risk for other problems such as heart or liver disease. Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.